MMP3 and Patent ductus arteriosus: In the TCGA database (Figure 4(b)), reduced survival was found in the high MMP-3 group in the whole PDA patients (median survival: 532 days vs.702 days, P = 0.001) and gemcitabine users (median survival: 394days vs. 691days, P = 0.019).